Literature DB >> 4094094

Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma.

H Matsuzaki, T Kagimoto, T Oda, F Kawano, K Takatsuki.   

Abstract

Natural killer (NK) activity and antibody-dependent cell-mediated cytotoxicity (ADCC) were studied by routine methods in 11 patients with untreated malignant monoclonal gammopathy. NK and/or ADCC activity was clearly reduced in three patients with advanced disease. Moreover, sera from some myeloma patients impaired the ADCC and NK activity. A large quantity of purified monoclonal IgG from one patient appeared to inhibit NK and ADCC activity as did high concentrations of pooled polyclonal immunoglobulin from healthy persons. In two of these 11 patients, other malignancies were diagnosed prior to chemotherapy. One of these patients, who had nonsecretory myeloma, had marked impairment of NK and ADCC activity; the other, with IgG myeloma, had normal NK and ADCC activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4094094

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  4 in total

Review 1.  Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.

Authors:  Colin Sheehan; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2019-10-15       Impact factor: 5.285

Review 2.  Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.

Authors:  Laure Farnault; Carole Sanchez; Céline Baier; Thérèse Le Treut; Régis T Costello
Journal:  Clin Dev Immunol       Date:  2012-08-01

3.  Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer.

Authors:  Zhiwei Hu; Jing Li
Journal:  BMC Immunol       Date:  2010-10-12       Impact factor: 3.615

4.  Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma.

Authors:  Sara Tognarelli; Sebastian Wirsching; Ivana von Metzler; Bushra Rais; Benedikt Jacobs; Hubert Serve; Peter Bader; Evelyn Ullrich
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.